Small cap round-up: InterQuest, ValiRx, Aeorema Comms

InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m pounds to its income statement from the settlement of it warranty claim against the vendors of CCL.Biotech firm ValiRx has announced that following a successful placing to raise £2.03m it will begin work on the first in-human clinical trials of its prostrate cancer drug VAL201. It has commissioned the manufacture of the drug and retained the services of technical personnel and other specialists to conduct the trials.Aeorema Communications, a multi-media specialist, has announced full year results for the year ended June 30th. Revenues grew to £2.9m (2011: £2.1m) producing a pre-tax loss of £0.82m (2011: loss of £0.9m). ValiRx